Molecular and genetic mechanisms of inflammatory bowel diseases and their biochemical markers


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Ulcerative colitis and Crohn’s disease represent one of the most pressing problems of modern medicine. Even though much attention paid to the development and implementation of high-tech diagnostic methods, inflammatory bowel diseases (IBD) tend to increase in prevalence and incidence. The literature review presents data on the molecular genetic mechanisms of the formation of inflammatory bowel diseases (IBD), biochemical markers of IBD, and their prognostic value. An accurate understanding of the molecular basis for the development of IBD has been shown to be currently lacking, which complicates the development of pathogenetically reasoned methods for diagnosing and predicting the risk of the development and the clinicalfeatures of ulcerative colitis and Crohn’s disease. This leads to the occurrence of complications requiring surgical intervention as well as an unfavorable medical and social prognosis. Perhaps the mechanisms of the development of these diseases are caused by certain nucleotide polymorphisms of genes, with a certain combination of them with immunological, environmental factors and microbial flora. Moreover, the diagnostic and prognostic significance of genetic, biochemical, and environmental features associated with the risk of developing IBD, the clinical picture, and the effectiveness of therapy have significant differences in patients from various countries and regions, which, inter alia, prevents an adequate assessment of the results of molecular genetic testing in diagnostics and prediction of IBD.

Full Text

Restricted Access

About the authors

Yu. V Myakisheva

Samara State Medical University

Email: yu.v.myakisheva@samsmu.ru
Head of the Department of General and Molecular Biology Samara State Medical University, assistant professor, Doctor of Medical Sciences. Chapaevskaya str., 89, Samara, 443099, Russian Federation;

T. A Kolesova

V.D. Seredavin Samara Regional Clinical Hospital

Email: biolsamgmu@mail.ru
Head of the Gastroenterology Department V.D. Seredavin Samara Regional Clinical Hospital, PhD st. Tashkent, 159, Samara, 443095, Russian Federation

Yu. A Khalitova

Samara State Medical University

Email: yuliya-2@mail.ru
graduate student Chapaevskaya str., 89, Samara, 443099, Russian Federation;

References

  1. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E.I., Panaccione R., Ghosh S., Barkema H.W., Kaplan G.G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; 142 (1): 46-54. https://doi.org/10.1053/j.gastro.2011.10.001.
  2. Kaplan G.G., Ng S.C. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017; 152 (2): 313-21.
  3. Wehkamp J., Gotz M., Herrlinger K., Steurer W., Stange E.F. Dtsch Arztebl Int.Inflammatory Bowel Disease. 2016; 113 (5): 72-82. https:// doi.org/10.3238/arztebl.2016.0072.
  4. Zhang Y.Z., Li Y.Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014; 20 (1): 91-9. https://doi.org/10.3748/ wjg.v20.i1.91.
  5. Wang M.H., Achkar J.P Gene-environment interactions in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol. 2015; 31: 277-82.
  6. Gevers D., Kugathasan S., Denson L.A., Vazquez-Baeza Y., Van Treuren W., Ren B., Schwager E., Knights D., Song S.J., Yassour M., Morgan X.C., Kostic A.D., Luo C., Gonzalez A., McDonald D., Haberman Y, Walters T., Baker S., Rosh J., Stephens M., Heyman M., Markowitz J., Baldassano R., Griffiths A., Sylvester F., Mack D., Kim S., Crandall W., Hyams J., Huttenhower C., Knight R., Xavier R.J. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15 (3): 382-92. https://doi. org/10.1016/j.chom.2014.02.005.
  7. Ливзан М.А., Макейкина М.А. Прогностические факторы течения язвенного колита. Экспериментальная и клиническая гастроэнтерология. 2013; 8: 17-23.
  8. Liu T.C., Stappenbeck T.S. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol. 2016; 11: 127-48. https://doi.org/10.1146/annurev-pathol-012615-044152.
  9. Anderson C.A., Boucher G., Lees C.W., Franke A., Damato M., Taylor K.D., Lee J.C., Goyette P., Imielinski M., Latiano A., Lagace C., Scott R., Amininejad L., Bumpstead S., Baidoo L., Baldassano R.N., Barclay M., Bayless T.M., Brand S., Buning C...Rioux J.D. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature genetics. 2011; 43 (3): 246-52. https://doi. org/10.1038/ng.764
  10. Younis N., Zarif R. & Mahfouz R. Inflammatory bowel disease: between genetics and microbiota. Mol. Biol. Rep. 2020; 47: 3053-63. https://doi.org/10.1007/s11033-020-05318-5
  11. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010; 16: 90-7. https://doi. org/10.1038/nm.2069
  12. Yamazaki K., Umeno J., Takahashi A., Hirano A., Johnson T.A, et al. A genome-wide association study identifies 2 susceptibility Loci for Crohn's disease in a Japanese population. Gastroenterology. 2013; 144: 781-8.
  13. Hirano A., Yamazaki K., Umeno J., Ashikawa K., Aoki M. et al. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis. 2013; 19: 526-33.
  14. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., Klunker S., Meyer N., O'Mahony L., Palomares O. et al. Interleukins, from 1 to 37, and interferon-y: receptors, functions, and roles in diseases. J. Allergy Clin Immunol. 2011; 127: 701-21.
  15. Nourian M., Chaleshi V, Pishkar L., Azimzadeh P., Baradaran Ghavami S., Balaii H., Alinaghi S., Shahrokh S., Asadzadeh Aghdaei H., Zali M.R. Evaluation of tumor necrosis factor (TNF)-a mRNA expression level and the rs1799964 polymorphism of the TNF-a gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomed Rep. 2017; 6 (6): 698-702. https://doi. org/10.3892/br.2017.908.
  16. Magyari L., Kovesdi E., Sarlos P., Javorhazy A., Sumegi K., Melegh B. Interleukin and interleukin receptor gene polymorphisms in inflammatory bowel diseases susceptibility. World J. Gastroenterol. 2014; 20: 3208-22.
  17. Gok 1., U?ar F., Ozgur O. Inflammatory cytokine gene polymorphism profiles in Turkish patients with ulcerative colitis. Med Glas (Zenica). 2015; 12 (1): 33-9. PMID: 25669334
  18. Guarda G., So A. Regulation of inflam-masome activity. Immunology 2010; 130: 329-36. https://doi.org/10.111Vj.1365-2567.2010.03283.x.
  19. Ebrahimi Daryani N., Saghazadeh A., Moossavi S., Sadr M., Shahkarami S., Soltani S., Farhadi E., Rezaei N. Interleukin-4 and Interleukin-10 Gene Polymorphisms in Patients with Inflammatory Bowel Disease. Immunol Invest. 2017; 46 (7): 714-29. https://doi.org/10.1080/08820139.2017.1360343.
  20. Neurath Markus Friedrich. Cytokines in inflammatory bowel disease. Nature Reviews Immunology 2014; 14: 329-42.
  21. Ashton J.J., Latham K., Beattie R.M., Ennis S. Review article: the genetics of the human leucocyte antigen region in inflammatory bowel disease. Aliment Pharmacol Ther. 2019; 50 (8): 885-900. https://doi. org/10.1111/apt.15485
  22. Zhang H.X., Li J.C., Xu G., Liu Z.J. Association between HLA-Cw polymorphism and inflammatory bowel disease. Zhonghua Neike Zazhi. 2011; 50: 856-8.
  23. Смолянинов А.Б, Жаров Е.В., Котелевская Е.А., Смирнова С.А., Масленикова И.И. Аллогенная трансплантация стволовых клеток и роль главного комплекса гистосовместимости (система HLA типирования: как устроена и работает)/ АГ-инфо. 2009; 3: 3-8.
  24. Achkar J.P., Klei L., de Bakker P.I., Bellone G., Rebert N., Scott R., Lu Y., Regueiro M., Brzezinski A., Kamboh M.I., Fiocchi C., Devlin B., Trucco M., Ringquist S., Roeder K., & Duerr R.H. Amino acid position 11 of HLA-DRP1 is a major determinant of chromosome 6p association with ulcerative colitis. Genes and immunity. 2012; 13 (3): 245-52. https://doi. org/10.1038/gene.2011.79
  25. Goyette P., Boucher G., Mallon D., Ellinghaus E., Jostins L., Huang H., Rioux J.D. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature genetics. 2015; 47 (2): 172-9. https://doi.org/10.1038/ ng.3176
  26. Лазебник Л.Б., Князев О.В., Яковлева М.В., Лебедева Л.Л., Сагынбаева В.Э., Ручкина И.Н., Михайлова З.Ф., Астрелина Т.А., Пухликова Т.В., Грибанов И.И. Иммуногенетическая предрасположенность к хроническим неспецифическим воспалительным заболеваниям кишечника. Экспериментальная и клиническая гастроэнтерология. 2012; 3: 20-34.
  27. Каторкин С.Е., Жестков А.В., Суворова Г.Н., Мякишева Ю.В., Лямин А.В., Андреев П.С., Давыдова О.Е., Круглов Е.Е. Комплексная характеристика клинических, патоморфологических и микробиологических особенностей язвенного колита. Военно-медицинский журнал. 2019; 340 (10): 68-71
  28. Pumbwe L., Skilbeck C.A., Nakano V et al. Bile salts enhance bacterial co-aggregation, bacterial-intestinal epithelial cell adhesion, biofilm formation and antimicrobial resistance of Bacteroides fragilis. Microb Pathog. 2007; 43: 78-87.
  29. Равин Н.В., Шестаков С.В. Геном прокариот. Вавиловский журнал генетики и селекции. 2013; 17: 972-84.
  30. Круглов Е.Е., Каторкин С.Е., Мякишева Ю.В., Борисенко Ю.Д., Буданов К.Е., Давыдова О.Е., Андреев П.С. Клинико-морфологические аспекты дифференциальной диагностики воспалительных заболеваний кишечника. Аспирантский вестник Поволжья. 2017; 5-6: 144-50
  31. Zhou Z., Zeng C., Guo C., Huang S., Huang C., Han Y et al. A meta-analysis of P1371Q polymorphisms in DLG5 gene with re-ducedrisk of Crohn'sdisease in European. International J. of Clinical and Experimental Medicine. 2017; 10: 4107-18.
  32. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А., Шифрин О.С., Абдулганиева Д.И., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Ачкасов С.И., Барановский А.Ю., Болихов К.В., Валуйских Е.Ю., Варданян А.В., Веселов А.В., Веселов В.В., Головенко A. О., Головенко О.В., Григорьев Е.Г, Губонина И.В., Жигалова Т.Н., Кашников B. Н., Кизова Е.А., Князев О.В., Костенко Н.В., Куляпин А.В., Морозова Н.А., Муравьев А.В., Низов А.А., Никитина Н.В., Николаева Н.Н., Никулина Н.В., Одинцова, А.Х., Осипенко М.Ф., Павленко B. В., Парфенов А.И., Полуэктова Е.А., Потапов А.С., Румянцев, В.Г., Светлова И.О., Ситкин С.И., Тимербулатов В.М., Ткачев А.В. , Ткаченко Е.В., Фролов C. А., Хубезов Д.А., Чашкова Е.Ю., Шапина М.В., Щукина О.Б., Яковлев А.А. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017; 2 (60): 7-29.
  33. Маркова А.А., Кашкина Е.И. Анализ лабораторных показателей у больных неспецифическим язвенным колитом. Bulletin of Medical Internet Conferences. 2014. 1000 ID: 2014-08-8-A-4084
  34. Filmann N., Rey J., Schneeweiss S., Ardizzone, Bager P., Bergamaschi G., Koutroubakis, Lindgren S., Morena Fde L., Moum B., Vavricka S.R., Schroder O., Herrmann E., Blumenstein I. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014; 20 (5): 936-45. https://doi. org/10.1097/01.MIB.0000442728.74340.fd.
  35. Mosli M.H., Zou G., Garg S.K., Feagan S.G., MacDonald J.K., Chande N., Sandborn W.J., Feagan B.G. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 2015; 110 (6): 802-19; quiz 820. https://doi.org/10.1038/ajg.2015.120.
  36. Cioffi M., de Rosa A., Serao R., Picone I., Vietri M.T. Laboratorymarkers in ulcerative colitis: current insights and future advances. World J. Gastrointest. Pathophysiol. 2015; 6 (1): 13-22.
  37. Zha A., Wang Y, Zha R. Meta analysis of the changes of blood coagulation in patients with active ulcerative colitis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015; 31 (11): 1528-32.
  38. Strober W., Fuss I.J. Pro-Inflammatory Cytokines in the Pathogenesis of IBD, Gastroenterology 2011; 140 (6): 1756-67.
  39. Roberts-Thomson I.C., Fon J., Uylaki W., Cummins A.G., Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol. 2011; 5: 703-16.
  40. Никитин А.В., Васильева Л.В., Матюхин А.А. Неинвазивные маркеры активности воспалительных заболеваний кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (6): 106-11.
  41. Емельянова В.А., Демидов А.А., Костенко Н.В., Чернышева Е.Н. Воспалительные заболевания кишечника: роль цитохимической активности внутриклеточных ферментов нейтрофилов и моноцитов периферической крови в диагностике. Кубанский научный медицинский вестник. 2017; 24 (3): 137-41. https://doi.org/10.25207 /1608-6228-2017-243-137-141
  42. Prideaux L., de Cruz P., Ng S.C., Kamm M.A. Serological antibodies in inflammatory bowel disease: a systematic review.Inflam-matory Bowel Diseases. 2012; 18 (7): 1340-55.
  43. Zhou G., Song Y, Yang W., Guo Y, Fang L., Chen Y, Liu Z. ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease Dig Dis. 2016; 34: 90-7. https://doi.org/10.1159/000442934
  44. Сагынбаева В.Э., Лазебник Л.Б. Антитела к Saccharomyces cerevisiae как предиктор осложненного течения болезни Крона. Экспериментальная и клиническая гастроэнтерология. 2013; 3: 48-52.
  45. Mokhtarifar A., Ganji A., Sadrneshin M. et al. Diagnostic Value of ASCA and Atypical p-ANCA in Differential Diagnosis of Inflammatory Bowel Disease. Middle East J. Dig Dis. 2013; 5 (2): 93-7.
  46. Abu-Freha N., Badarna W., Sigal-Batikoff I., Abu Tailakh M., Etzion O., Elkrinawi J., Segal A. , Mushkalo A., Fich A. ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation. BMC Gastroenterol. 2018;153. https://doi.org/10.1186/s12876-018-0884-x
  47. Bernstein C.N., El-Gabalawy H., Sargent M., Landers C., Rawsthorne P., Elias B., Targan S.R. Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts. Can J. Gastroenterol. 2011; 25 (5): 269-73. https://doi. org/10.1155/2011/712350
  48. Saadah O., Al-Mughales J. Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia. Arab J. Gastroenterol. 2013; 14: 78-82. https://doi.org/10.1016/j.ajg.2013.05.004
  49. Van Schaik F.D., Oldenburg B., Hart A.R., Siersema P.D., Lindgren S., Grip O., Teucher B. , Kaaks R., Bergmann M.M., Boeing H., Carbonnel F., Jantchou P., Boutron-Ruault M.C., Tj0nneland A., Olsen A., Crowe F.L, Peeters P.H., van Oijen M.G., Bueno-de-Mesquita H.B. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut. 2013; 62 (5): 683-8. https:// doi.org/10.1136/gutjnl-2012-302717

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies